Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02856269 · ClinicalTrials.gov registry record · NA

Zinc Supplementation and Cardiovascular Risk in HIV

A NA study of HIV and Inflammation, sponsored by Grace McComsey.

Completed
Registry status
NA
Development phase
52
Enrollment target
1
Study location

NCT02856269: Completed NA study of HIV and Inflammation, sponsored by Grace McComsey.

NCT02856269 is a NA study of HIV and Inflammation that has completed, run by Grace McComsey. The registered enrollment target is 52 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02856269, a NA study of HIV and Inflammation, has completed, sponsored by Grace McComsey.

COMPLETED
Registry status
NA
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

The purpose of this pilot study is to determine whether zinc supplementation significantly affects immune activation in HIV-infected subjects.

Primary Outcome

Percentage of participants with the following inflammatory markers decrease (sCD14) Soluble cluster of differentiation 14, (sTNF-RI) soluble Tumor Necrosis Factor alpha receptor I, (hs-CRP) High sensitivity C-reactive protein. These inflammatory markers are measured in the blood by enzyme-linked immunoassay ELISA.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Zinc gluconate

Study Locations (1)

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2016-09
Est. Completion 2018-04-16
Phase NA
Grace McComsey

1 total trials

What the finished NCT02856269 record still lists

NCT02856269 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (88% lower).

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Zinc gluconate is the first listed.

NCT02856269 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT02856269 about?

NCT02856269 is a clinical study titled "Zinc Supplementation and Cardiovascular Risk in HIV". The purpose of this pilot study is to determine whether zinc supplementation significantly affects immune activation in HIV-infected subjects.

What is the current status of trial NCT02856269?

This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2016-09. Estimated completion is 2018-04-16.

What conditions does trial NCT02856269 study?

This clinical trial studies the following conditions: HIV, Inflammation.

What interventions are being tested in trial NCT02856269?

The interventions under investigation include: Zinc gluconate (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02856269?

This trial is sponsored by Grace McComsey, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02856269 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02856269's enrollment target sits among peer trials

52 217th of 303 higher than 86 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02856269, the US trial registry maintained by the National Library of Medicine. NCT02856269 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.